
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

August 2018

Commission File Number: 001-38067

**Verona Pharma plc
(Exact Name of Registrant as Specified in Its Charter)**

**3 More London Riverside
London SE1 2RE UK
+44 203 283 4200
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On August 10, 2018, Verona Pharma plc issued a press release reporting the purchase of shares by its Chairman, Dr David Ebsworth, and the issue of new Ordinary Shares following the vesting of restricted stock units held by a former employee, Dr. Ken Newman.

The PDMR Dealing and Share Issue Press Release is furnished herewith as Exhibit 1 to this Report on Form 6-K.

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
1	PDMR Dealing and Share Issue Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VERONA PHARMA PLC

Date: August 14, 2018

By: /s/ Claire Poll

Name: Claire Poll

Title: Legal Counsel



PDMR Dealing & Issue of Shares

August 10, 2018, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 9, 2018, Dr. David Ebsworth, Chairman of the Company, purchased 12,000 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 120.00 pence per Ordinary Share. Following the acquisition, Dr. Ebsworth will have an interest in the Company of 147,787 Ordinary Shares, representing 0.14% of the Company's issued share capital.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

The Company also announces that, on August 9, 2018, it issued 58,112 new Ordinary Shares (the "New Ordinary Shares") following the vesting of restricted stock units held by a former employee, Dr. Ken Newman. Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM, with dealings expected to commence on 16 August 2018 ("Admission"). Following Admission, the Company will have a total of 105,075,513 Ordinary Shares in issue each carrying one voting right. The Company does not hold any Ordinary Shares in Treasury. This figure of 105,075,513 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	David Ebsworth
2	Reason for the notification	
a)	Position/status	Chairman
b)	Initial notification/Amendment	Initial notification

3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Verona Pharma plc
b)	LEI	213800EVI6O6J3TIAL06
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 5 pence each GB00BYW2KH80
b)	Nature of the transaction	David Ebsworth purchased 12,000 Ordinary Shares
c)	Price(s) and volume(s)	Price(s) : 120.00 per Ordinary Share Volume(s) : 12,000 Ordinary Shares
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	9 August 2018
f)	Place of the transaction	London Stock Exchange, AIM

For further information, please contact:

Verona Pharma plc
Jan-Anders Karlsson, Chief Executive Officer
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison

Tel: +44 (0)20 3283 4200
info@veronapharma.com

Tel: +44 (0) 20 7710 7600